Blog
RSS FeedPosted by Michael Wonder on 17 Jun 2021
Amneal announces U.S. FDA filing acceptance of biologics license application for bevacizumab
17 June 2021 - Bevacizumab represents the third biosimilar BLA currently filed by Amneal with the FDA. ...
Posted by Michael Wonder on 02 Jun 2021
Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application
2 June 2021 - Lupin today announced that the U.S. FDA has accepted the biologics license application for its proposed ...
Posted by Michael Wonder on 02 Jun 2021
Experts expect to see “second wave” of biosimilars approvals
2 June 2021 - Experts expect to see a second wave of biosimilar approvals, though continued Medicare Part D reimbursement challenges ...
Posted by Michael Wonder on 21 May 2021
Biosimilar bevacizumab on the PBS - information for health professionals and patients
21 May 2021 - A biosimilar brand of bevacizumab (Mvasi) will be listed on the PBS on 1 June 2021. Information ...
Posted by Michael Wonder on 18 May 2021
Quebec announces intention to implement a biosimilar switching policy
18 May 2021 - Biosimilars Canada today congratulated the Government of Quebec and Minister of Health and Social Services Christian ...
Posted by Michael Wonder on 18 May 2021
Sandoz Canada congratulates the Quebec government on implementing a shift towards biosimilars
18 May 2021 - The shift announced by Quebec will follow a similar approach to policies introduced in British Columbia, Alberta ...
Posted by Michael Wonder on 17 May 2021
Sandoz Canada launches its 6th biosimilar with Inclunox and Inclunox HP (enoxaparin sodium solution for injection 100 mg/mL and 150 mg/mL (high potency))
17 May 2021 - New Sandoz biosimilar launch can potentially lower healthcare costs, especially for Canadian hospitals, as 75% of the ...
Posted by Michael Wonder on 17 May 2021
US Supreme Court denies Sandoz petition to review biosimilar Erelzi (etanercept-szzs) case
17 May 2021 - Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable ...
Posted by Michael Wonder on 11 May 2021
US, EU regulators discuss tailoring biosimilar approvals
11 May 2021 - A tailored approach to biosimilar approvals is conceived as the next big leap for regulatory advancement in ...
Posted by Michael Wonder on 06 May 2021
Alberta, Canada, begins mandating switches from originator to biosimilar Humira
6 May 2021 - Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar ...
Posted by Michael Wonder on 06 May 2021
The difference between an interchangeable biosimilar and one that isn't
5 May 2021 - Permitting automatic substitution of biosimilars for originator brand biologics at the pharmacy counter is often talked about ...
Posted by Michael Wonder on 29 Apr 2021
Toothful or toothless? Biden's biosimilar bills under the microscope
28 April 2021 - How much muscle did Congress invest in a pair of bills recently signed by President Biden? ...
Posted by Michael Wonder on 29 Apr 2021
Valeo Pharma’s Redesca and Redesca HP to be covered under the Ontario Public Drug Benefit Program
28 April 2021 - Additional provincial coverage expected to follow. ...
Posted by Michael Wonder on 22 Apr 2021
New Brunswick becomes third province in Canada to implement biosimilar switching policy
21 April 2021 - Biosimilars Canada today congratulated the Government of New Brunswick for implementing a biosimilar "switching" or transitioning ...
Posted by Michael Wonder on 30 Mar 2021
Samsung Bioepis continues global market expansion with launch of Hadlima in Australia and Canada in partnership with Merck
29 March 2021 - Samsung Bioepis’ adalimumab is now available in three markets: Europe, Canada and Australia. ...